Global Patent Index - EP 1067948 A1

EP 1067948 A1 2001-01-17 - USE OF EXTRACTS OF BEARBERRY LEAVES (ARCTOSTAPHYLOS UVA URSI), BIRCH LEAVES (BETULA), HORSETAIL (EQUISETUM) AND STINGING NETTLE (URTICA)

Title (en)

USE OF EXTRACTS OF BEARBERRY LEAVES (ARCTOSTAPHYLOS UVA URSI), BIRCH LEAVES (BETULA), HORSETAIL (EQUISETUM) AND STINGING NETTLE (URTICA)

Title (de)

VERWENDUNG VON BÄRENTRAUBENBLÄTTERN (ARCTOSTAPHYLOS UVA URSI)-, BIRKENBLÄTTER (BETULA)-,SCHACHTELHALKRAUT (EQUISETUM)- UND BRENNESSEL (URTICA)-EXTRAKTE

Title (fr)

UTILISATION D'EXTRAITS DE FEUILLES DE BUSSEROLE(ARCTOSTAPHYLOS UVA URSI), DE FEUILLES DE BOULEAU (BETULA), DE PRELE (EQUISETUM) ET D'ORTIE BRULANTE (URTICA)

Publication

EP 1067948 A1 (DE)

Application

EP 99919156 A

Priority

  • DE 19814905 A
  • EP 9902153 W

Abstract (en)

[origin: DE19814905A1] The invention relates to the use of extracts of bearberry leaves (Arctostaphylos uva ursi), birch leaves (Betula), horsetail (Equisetum) and stinging nettle (Urtica), especially dry extracts from the fresh or dried plants, to produce medicaments for treating or preventing (protecting against) damage caused to organs and tissue by radiation (radioprevention, radioprotection), infection (infection prophylaxis) and chemical action (chemoprevention, chemoprotection), especially damage to the O-MALT system of the small bowel (inflammatory diseases, enteritis regionalis Crohn), the lungs (inflammation, disease), the bronchial tubes and the rhinopharynx (rhino-pharyngo-bronchitis, rhinitis, pharyngitis, sinusitis), the bone marrow (aplasia of the bone marrow), the thymus (dysfunction, aplasia or hypoplasia resulting from damage caused by medicaments or radiation), the liver (atrophy, necrosis), for treating/preventing hepatitis A, B and C, for damage to the pancreas, insufficiency of the exocrine, secretory functions of proteases, esterases, carbohydrases and nucleases and impairment of the carbohydrate metabolism (Langerhans' islands), damage to the kidneys (insufficiency), and generally immunosuppressed conditions, for cellular immunostimulation, for treating leucocytopenia, granulocytopenia, lymphoctopenia, thrombocytopenia, erythrocytopenia (infect anaemia, tumour anaemia i.a.), immunoglobulin deficiency conditions, and for conditions resulting from AIDS, tumours and diseases with a suppressed immune system.

IPC 1-7 (main, further and additional classification)

A61K 35/78

IPC 8 full level (invention and additional information)

A61K 36/00 (2006.01); A61K 36/11 (2006.01); A61K 36/185 (2006.01); A61K 36/28 (2006.01); A61K 36/38 (2006.01); A61K 36/45 (2006.01); A61P 31/18 (2006.01); A61P 37/04 (2006.01)

CPC (invention and additional information)

A61K 36/185 (2013.01); A61K 36/11 (2013.01); A61K 36/28 (2013.01); A61K 36/38 (2013.01); A61K 36/45 (2013.01)

Combination set (CPC)

  1. A61K 36/11 + A61K 2300/00
  2. A61K 36/185 + A61K 2300/00
  3. A61K 36/28 + A61K 2300/00
  4. A61K 36/38 + A61K 2300/00
  5. A61K 36/45 + A61K 2300/00

Citation (search report)

See references of WO 9951251A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB IT LI LU NL SE

EPO simple patent family

DE 19814905 A1 19991007; AU 3703099 A 19991025; EP 1067948 A1 20010117; WO 9951251 A1 19991014

INPADOC legal status


2003-12-17 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20030617

2003-01-22 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20021205

2001-02-07 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000912

2001-01-17 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH DE DK ES FI FR GB IT LI LU NL SE